• 27 August, 2025

Tech Solutions CSO

October 10, 2011 | Monday | News

The business objective of any BioIT company is to support the pharma companies, which are under tremendous pressure due to rising R&D costs, drying of product pipeline and regulatory hurdles. Companies, such as Strand Life Sciences and CellWorks, have been working towards meeting this aim.



In this issue of CSO series, we focus on the contributions of Dr Kalyanasundaram Subramanian, CSO, Strand Life Sciences, and Dr Shireen Vali, CSO, CellWorks, towards development of technology-based solutions to enable drug discovery R&D, improve productivity and success rate of the process, reduce costs, increase efficiency, and identify potential side-effects.

Comments

× Your session has expired. Please click here to Sign-in or Sign-up
New User? Create Account

Trending Topics

Most Read

Survey Box

Can Policy Reforms & Investments Trigger India’s MedTech Makeover?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls

Have an Account?

Forgot your password?

First Name should not be empty!

Last Name should not be empty!

Email address should not be empty!

Show Password should not be empty!

Show Confirm Password should not be empty!

Newsletter

E-magazine

Biospectrum Infomercial

Bio Resource

I accept the terms & conditions & Privacy policy